Janet Addison
Maidenhead, ENG, United Kingdom
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 21 publications
Correction: Real-World Evidence of Clinical Outcomes of the Use of the Adalimumab Biosimilar SB5 in Rheumatic and Gastrointestinal Immune-Mediated Inflammatory Diseases: 12-Month Data from the PERFUSE Study.
Journal: Drugs - real world outcomes
Published: January 17, 2025
Real-World Evidence of Clinical Outcomes of the Use of the Adalimumab Biosimilar SB5 in Rheumatic and Gastrointestinal Immune-Mediated Inflammatory Diseases: 12-Month Data from the PERFUSE Study.
Journal: Drugs - real world outcomes
Published: September 26, 2024
A phase 3, randomized, double-blind, active-controlled clinical trial to compare BAT1806/BIIB800, a tocilizumab biosimilar, with tocilizumab reference product in participants with moderate-to-severe rheumatoid arthritis with inadequate response to methotrexate: treatment period 2 analysis (week 24 to week 48).
Journal: Arthritis research & therapy
Published: February 20, 2024
A randomised, crossover trial exploring the patient perspective and effectiveness of biosimilar adalimumab transition: IBD reference and biosimilar adalimumab cross over study (iBaSS).
Journal: International journal of clinical pharmacy
Published: December 15, 2023
The PROPER Study: A 48-Week, Pan-European, Real-World Study of Biosimilar SB5 Following Transition from Reference Adalimumab in Patients with Immune-Mediated Inflammatory Disease.
Journal: BioDrugs : clinical immunotherapeutics, biopharmaceuticals and gene therapy
Published: July 07, 2023
Premature morbidity and mortality associated with potentially undiagnosed familial hypercholesterolemia in the general population.
Journal: American journal of preventive cardiology
Published: March 17, 2023
Comparing tocilizumab biosimilar BAT1806/BIIB800 with reference tocilizumab in patients with moderate-to-severe rheumatoid arthritis with an inadequate response to methotrexate: a phase 3, randomised, multicentre, double-blind, active-controlled clinical trial.
Journal: The Lancet. Rheumatology
Published: March 09, 2023
PERFUSE: Non-Interventional Cohort Study of Patients Receiving Infliximab Biosimilar SB2: Results in Pediatric Patients.
Journal: Journal of pediatric gastroenterology and nutrition
Published: February 02, 2023
The PERFUSE study: The experience of patients receiving Adalimumab biosimilar SB5.
Journal: Digestive and liver disease : official journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver
Published: January 31, 2023
Real-world evidence of the use of the infliximab biosimilar SB2: data from the PERFUSE study.
Journal: Rheumatology advances in practice
Published: September 28, 2022
PERFUSE: a French non-interventional study of patients with inflammatory bowel disease receiving infliximab biosimilar SB2: a 12-month analysis.
Journal: Therapeutic advances in gastroenterology
Published: February 28, 2022
Kokumi taste perception is functional in a model carnivore, the domestic cat (Felis catus).
Journal: Scientific reports
Published: December 21, 2020
Last Updated: 09/26/2026